Lessons Learned From Awake ECMO Approach in Covid-19-Related Acute Respiratory Distress Syndrome-a Scoping Review

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F71009396%3A_____%2F25%3AN0000007" target="_blank" >RIV/71009396:_____/25:N0000007 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/25:A2603D89

Result on the web

<a href="https://www.tandfonline.com/doi/epdf/10.2147/TCRM.S507120?src=getftr&utm_source=clarivate&getft_integrator=clarivate" target="_blank" >https://www.tandfonline.com/doi/epdf/10.2147/TCRM.S507120?src=getftr&utm_source=clarivate&getft_integrator=clarivate</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/TCRM.S507120" target="_blank" >10.2147/TCRM.S507120</a>

Result language

angličtina

Original language name

Lessons Learned From Awake ECMO Approach in Covid-19-Related Acute Respiratory Distress Syndrome-a Scoping Review

Original language description

During the COVID-19 pandemic, specific COVID-19-related conditions renewed interest in the full-awake venovenous extracorporeal membrane oxygenation (faV–V ECMO) approach, in which ECMO is applied to awake, cooperative, and non-intubated patients. This scoping review aims to provide a descriptive overview offa V–V ECMO in patients with COVID-19-related acute respiratory distress syndrome (CARDS). We searched the PubMed, Web of Science, and Scopus databases using the keywords “awake ECMO” or “spontaneous breathing AND ECMO”, combined with “COVID-19”, “SARS-CoV-2” or “coronavirus”, utilizing the Boolean operator “AND”. The search included papers published from November 1, 2019, to December 31, 2024. Sixty-four papers were assessed for eligibility at the abstract level, and fourteen articles (seven small-sample cohort studies and seven case reports) comprising 95 patients were included in the final analysis. The most frequent reasons for preferringfaV-V ECMO over mechanical ventilation were barotrauma and patient refusal of intubation and mechanical ventilation. Thefa V-V ECMO strategy was successful (ie, patients not intubated, disconnected from ECMO, and discharged from the hospital) in 36.4% of cases (cohort studies only). The incidence of defined severe adverse events (bleeding, thrombosis, cannula malposition, delirium, and progression of barotrauma) was considered low. The mortality rate for CARDS patients treated withfaV-V ECMO (including only patients from cohort studies) reached 33.0%, notably lower than the 48% reported for CARDS patients treated with V-V ECMO in the ELSO registry. Patients who were intubated due to worsening respiratory failure duringfaV-V ECMO had significantly higher mortality. Infectious complications, sepsis, and multiorgan failure were the most frequent causes of death. However, significant heterogeneity in the definitions and reporting of management, ECMO-related complications, and outcomes was observed across the papers. Despite the heterogeneity of the data,fa V-V ECMO in CARDS patients can be considered a safe approach associated with a lower mortality rate than that reported in the overall V-V ECMO CARDS population. © 2025 Sklienka et al.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30203 - Respiratory systems

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Therapeutics and Clinical Risk Management

ISSN

1178-203X

e-ISSN

1178-203X

Volume of the periodical

21

Issue of the periodical within the volume

-

Country of publishing house

NZ - NEW ZEALAND

Number of pages

14

Pages from-to

655-668

UT code for WoS article

001490311400001

EID of the result in the Scopus database

2-s2.0-105006743197